ONO-7746
Phase 1Small molecule
Ono Pharmaceutical Co. LtdONO-7746 is one of 43 small molecule programs targeting Thrombocytopenia. It is currently in Phase 1.
1
Indications
3
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
105 competitors in Thrombocytopenia
#DrugCompanyPhaseTrials
1Acova
Alnylam PharmaceuticalsPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Fabhalta
Johnson & JohnsonPhase 3
Cyklokapron
AAmring
Phase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Dacogen
Sun PharmaPhase 3
Imuran
LLegacy Health System
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Xarelto
WWim Janssens
Phase 3
Best Available Therapy
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ONO-7746. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company